Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk |
| |
| Authors: | Weber Michael A Bakris George L Dahlöf Björn Pitt Bertram Velazquez Eric Gupte Jitendra Lefkowitz Martin Hester Allen Shi Victor Weir Matthew Kjeldsen Sverre Massie Barry Nesbitt Shawna Ofili Elizabeth Jamerson Kenneth |
| |
| Affiliation: | a SUNY Downstate Medical College, Brooklyn, New York, USAb Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USAc Sahlgrenska University Hospital, Gothenburg, Swedend University of Michigan Health System, Ann Arbor, Michigan, USAe Duke University School of Medicine, Durham, North Carolina, USAf Novartis Pharmaceuticals, East Hanover, New Jersey, USAg Univeristy of Maryland School of Medicine, Baltimore, Maryland, USAh Ullevaal University Hospital, Oslo, Norwayi University of California, San Francisco, California, USAj University of Texas Southwestern Medical Center, Dallas, Texas, USAk Morehouse School of Medicine, Atlanta, Georgia, USA |
| |
| Abstract: | ![]()
ACCOMPLISH is the first trial designed to compare the effects on major fatal and non-fatal cardiovascular endpoints of two forms of antihypertensive combination therapy: benazepril plus hydrochlorothiazide and amlodipine plus benazepril in hypertensive patients at high cardiovascular risk. Enrollment for this trial is now complete and this report describes the clinical characteristics of the study cohort. Patients with hypertension and a previous history of cardiovascular events, strokes or diabetes mellitus were randomized to double-blind treatment with either of the two combination regimens. The data in this report detail the clinical history and demographic characteristics in patients immediately prior to randomization to study drugs. A total of 11,454 patients were randomized. Mean age (±SD) was 68.4±6.9 years, 60% were men, and 1360 (12%) were African American. Mean body mass index (BMI) was 31.0±6.3 kg/m2. At study entry, 46% of patients had a history of acute coronary syndromes, coronary artery bypass grafts or percutaneous coronary interventions; 13% had a history of stroke. A history of diabetes mellitus was reported in 6928 (60%) of patients. Mean blood pressure at baseline (on prior hypertension therapy) was 145.4/80.0 mmHg; only 38% of patients had a BP less than 140/90mmHg. Overall, 97% of patients had received previous antihypertensive treatment (74% on at least two drugs); 53% were on oral diabetes therapy or insulin, 68% on anti-lipid therapy and 63% on anti-platelet agents. In summary, the ACCOMPLISH trial has recruited hypertensive patients at high risk of cardiovascular morbidity and mortality. It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease. |
| |
| Keywords: | Clinical trials combination therapy hypertension cardiovascular outcomes |
| 本文献已被 InformaWorld PubMed 等数据库收录！ |
|
